These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1837256)

  • 1. [Use of naltrexone in the treatment of opiate addicts. Efficacy and indications for type categories].
    Faro G; Jarre P; Martucci M; Sargiotto A; Eandi M
    Clin Ter; 1991 Nov 15-30; 139(3-4):93-9. PubMed ID: 1837256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Limited role of naltrexone in the treatment of opiate addiction].
    van Brussel GH
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detoxication in opiate addiction and prevention of recurrence: administration of naltrexone and cognitive behavior therapy].
    Roozen HG; Deden AL; Kerkhof AJ; Vorsteveld JP; van den Brink W
    Ned Tijdschr Geneeskd; 1997 Dec; 141(49):2377-80. PubMed ID: 9554156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Naltrexone and prevention of opiate dependence relapse. An Italian experience].
    Cibin M; Gentile N; Ferri M; Gallimberti L
    Minerva Psichiatr; 1989; 30(2):93-8. PubMed ID: 2779401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone: a clinical perspective.
    Greenstein RA; Arndt IC; McLellan AT; O'Brien CP; Evans B
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):25-8. PubMed ID: 6469933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Naltrexone therapy. Experience with "Telephone Assistance" in Rome].
    Coccoli M; Rugolo AP; Rocchi R; Giannini P; Ciervo U
    Minerva Psichiatr; 1993 Mar; 34(1):39-43. PubMed ID: 8492675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone in addicted physicians and business executives.
    Washton AM; Gold MS; Pottash AC
    NIDA Res Monogr; 1984; 55():185-90. PubMed ID: 6443377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Addiction characteristics as prognostic factors in opiate dependence treated with naltrexone].
    Madoz-Gúrpide A; Barbudo del Cura E; Leira Sanmartín M; Navio Acosta M; Villoria Borrego L; Ochoa Mangado E
    Actas Esp Psiquiatr; 2004; 32(4):199-210. PubMed ID: 15232748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new approach to preventing relapse in opiate addicts: a psychometric evaluation.
    Grüsser SM; Thalemann CN; Platz W; Gölz J; Partecke G
    Biol Psychol; 2006 Mar; 71(3):231-5. PubMed ID: 16046046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with naltrexone in suburban opioid addicts.
    Tennant FS; Rawson RA; Cohen AJ; Mann A
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):42-5. PubMed ID: 6469935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rationale for naltrexone therapy as an alternative to methadone treatment for opiate addiction.
    Simon DL
    Conn Med; 1996 Nov; 60(11):683-5. PubMed ID: 8979434
    [No Abstract]   [Full Text] [Related]  

  • 12. [Naltrexone in the therapeutic relation in cases of opioid abuse and dependence].
    Liffredo C; Gallino G
    Minerva Med; 1993 Dec; 84(12):687-92. PubMed ID: 8127459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of naltrexone, a long-acting opiate antagonist.
    Crabtree BL
    Clin Pharm; 1984; 3(3):273-80. PubMed ID: 6329589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Maintenance treatment for opiate dependence at a naltrexone clinic].
    López-Ibor Aliño JJ; Pérez de los Cobos JC; Ochoa E; Hernández Herreros M
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1990; 18(5):296-305. PubMed ID: 1963258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clonidine-naltrexone: a new technic for the detoxification of opiate addicts].
    Oliveros SC; Caballero L; Iruela LM
    Med Clin (Barc); 1990 Nov; 95(16):627-9. PubMed ID: 2097456
    [No Abstract]   [Full Text] [Related]  

  • 16. Opiate addiction and plasma beta-endorphin-like immunoreactivity: methadone maintained, recently detoxified and early naltrexone treated ex-addicts.
    Cushman P; Morris D; Adams M; Dewey W
    Alcohol Drug Res; 1987; 7(5-6):533-40. PubMed ID: 2956960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels.
    Foster J; Brewer C; Steele T
    Addict Biol; 2003 Jun; 8(2):211-7. PubMed ID: 12850780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
    Reece AS
    J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alcohol consumption in opioid-dependence patients in treatment with naltrexone].
    Ochoa Mangado E; Arias Horcajadas F
    Actas Esp Psiquiatr; 2000; 28(4):239-49. PubMed ID: 11116795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy.
    Chen TJ; Blum K; Payte JT; Schoolfield J; Hopper D; Stanford M; Braverman ER
    Med Hypotheses; 2004; 63(3):538-48. PubMed ID: 15288384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.